Trials / Completed
CompletedNCT00989521
Effect of PUR003 on Asthma
Double-blind, Placebo-controlled Crossover Evaluation of the Effect of PUR003 on Subjects With Asthma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Pulmatrix Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
PUR003 is an inhaled substance that is proposed to assist in the treatment of asthma. Study objectives are to : 1. to evaluate the safety of PUR003 in subjects with asthma, and 2. to evaluate the efficacy of PUR003 in assisting the treatment of asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PUR003 | PUR003 for inhalation |
| DRUG | Placebo | Normal saline for inhalation |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2009-10-05
- Last updated
- 2011-11-22
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00989521. Inclusion in this directory is not an endorsement.